


DAFTAR PUSTAKA

1. Zein E, Fitria C, Shinta Rumastika N, Wulandari P. Hubungan Faktor Risiko dengan Kejadian Karsinoma nasofaring (KNF) di RSD dr. Soebandi. Jurnal Universitas Jember.2020;6:130-135.
2. Yusuf MA, Rintjap JMC, Rahmy Sujuthi A, Wartati S, Faisal Syamsu R. Karakteristik Pasien Karsinoma Nasofaring Di RS. Pelamonia Makassar Tahun 2020-2022. 2023 [cited 2024 Jul 30]. Fakumi Medical Journal. 2023;3(5):336-342.
3. Arsyad Soepardi E, Nurbaiti Iskandar S, Jenny Bashiruddin SD, Ratna Dwi Restuti SD. Buku Ajar Ilmu Kesehatan Telinga Hidung Tenggorok Kepala & Leher. 2007;6:162-171.
4. Amanah NS. Faktor-faktor penyebab terjadinya karsinoma nasofaring (KNF). Wellness And Healthy Magazine. 2020;2(1):113–20.
5. Zhang Y, Rungay H, Li M, Cao S, Chen W. Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling. JMIR Public Health Surveill. 2023;9(1):1–10.
6. Grecwin DA, Rahman S, Hafiz A, Yerizel E, Bachtiar H. Perbedaan Alel Human Leucocyte Antigen A*02 antara Pasien Karsinoma Nasofaring dengan Kontrol pada Etnik Minangkabau. Vol. 1, Jurnal Otorinolaringologi Kepala dan leher Indonesia. 2022.
7. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. 2022:1-2.
8. Maghri Jodie R, Rahman S. Gambaran Terapi dan Respon Terapi Karsinoma Nasofaring di RSUP Dr. M. Djamil Padang. Jurnal Otorinolaringologi Kepala dan leher Indonesia. 2022;1(1):20-25.
9. Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. American Joint Committee on Cancer. 2010;7(7):51–53.
10. Kementrian Kesehatan. Panduan Praktik Klinis Karsinoma Nasofaring. 2019:1-10
11. Dewi NS, Yusmawan W, Budiarti R. Kejadian Mielosupresi pada Penderita Kanker Kepala dan Leher yang Mendapat Kemoterapi Cisplatin dan Carboplatin di RSUP Dr. Kariadi Semarang. Medica Hospitalia. 2020;7:34–40.

12. Setiani L, Juniar, Safarianti. Efektivitas kemoterapi yang berdampak pada peningkatan kualitas hidup pasien karsinoma nasofaring. *Jurnal Kedokteran Syiah Kuala*. 2022;22(4):336–42.
13. Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. *Theranostics*. Ivyspring International Publisher. 2022;12(5):2115-2132.
14. Romdhoni A. Karsinoma Nasofaring Diagnosis dan Terapi Terkini. Kentjono W, editor. Airlangga University Press. 2021:23-53.
15. About Nasopharyngeal Cancer. American Cancer Society. 2022:1-2.
16. Martini F, Tallitsch R, Nath J. *Human Anatomy*. 2019;9:629.
17. Faisal, Hamida Hayati. Gambaran Karakteristik Karsinoma Nasofaring Dan Faktor-Faktor Yang Mempengaruhi Prognosis. *Jurnal Universitas Indonesia*. 2016:3-10.
18. Mankowski NL, Bordoni B. *Anatomy, Head and Neck, Nasopharynx*. National Center for Biotechnology. 2023.
19. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. *The Lancet*. Lancet Publishing Group. 2019;394:64–80.
20. Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiology Biomarkers and Prevention*. American Association for Cancer Research Inc. 2021;30:1035–1047.
21. Harahap, Armansyah Maulana. Hubungan Karsinoma Nasofaring Dengan Eipstennbarr Virus (Ebv) Terhadap Stadium Klinis Pasien Penderita Kanker Nasofaring. *Jurnal Medika Sehat*. 2023:35-40.
22. Hardiati RH, Nabila C, Milenia UN. Klasifikasi, Faktor Risiko, Tatalaksana dan Komplikasi Kanker Nasofaring. *Jurnal Ilmiah Universitas Batanghari Jambi*. 2022;22(1):304.
23. Khoirunnisa Arohmah N, Herawati Prabowo R. Gambaran Klinis dan Faktor Risiko Penderita Kanker Nasofaring Clinical Overview and Risk Factors for Nasopharyngeal Cancer. *Setia Budi Confernce on Innovation in Health Accounting, and Management Sciences*. 2020:207-209
24. Hardiati RH, Nabila C, Milenia UN. Klasifikasi, Faktor Risiko, Tatalaksana dan Komplikasi Kanker Nasofaring. *Jurnal Ilmiah Universitas Batanghari Jambi*. 2022 Feb 19;22(1):304.



25. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. In: The Lancet. Lancet Publishing Group. 2016:1012–1024.
26. David Sigarlaki E, Imanto M, Cania E, et al. Tatalaksana Radioterapi pada Karsinoma Nasofaring. Jurnal Medula. 2019;8(2):23-26.
27. Prahardi R, Winarno G, Tari. Penatalaksanaan Radiasi Eksterna Kasus Kanker Nasofaring Teknik 2d Menggunakan Pesawat Cobalt 60. 2020:1-4.
28. Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, et al. NCCN Guidelines. Head and Neck Cancers Continue NCCN Guidelines. 2021;3:39-44.
29. Setya Santoso B, Surarso B, Ario Kentjono W. Radioterapi Pada Karsinoma Nasofaring. Jurnal THT-KL. 2009;2(3):134–41.
30. Moeloek NF. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Nasofaring. 2019:15-26.
31. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. The Lancet. Lancet Publishing Group. 2019;394:64–80.
32. Firdaus MA, Pr J. Kemoterapi Neoadjuvan pada Karsinoma Nasofaring. Jurnal Otorinolaringologi Kepala dan leher Indonesia. 2014:1–9.
33. Colevas AD. NCCN Guidelines Insights: Head and Neck Cancers. Journal of the National Comprehensive Cancer Network. 2018 16,5:479–90.
34. Aninditha T, Soebroto AD, Nurhayati E. Komplikasi Neurologis pada Karsinoma Nasofaring Neurological Complication in Nasopharyngeal Carcinoma. eJKI. 2018;6(2):123–6.
35. Siahaan SP, Muis M, Baan J, Zainudin AA. Hubungan Karakteristik Penderita Kanker Nasofaring Yang Mendapat Kemoterapi Dengan Response Evaluation Criteria In Solid Tumors 1.1 (Recist) Di Rsup Dr. Wahidin Sudirohusodo Makassar. Jurnal Medika Udayana. 2024;13(7) :60–68.
36. Romdhoni AC. Prinsip Dasar Kemoterapi Pada Kanker Kepala Dan Leher. Jurnal Universitas Airlangga. 2017:23–53.
37. Ruhyanudin F, Wahyu Theresia M, Azalia NR. Analisis Terapi Pilihan Untuk Mengurangi Keluhan Subyektif Pada Pasien Kanker Yang Menjalani Kemoterapi. Jurnal Keperawatan Muhammadiyah. 2022;7(3):89–92.
38. Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy, StatPearls. 2024.
39. How Chemotherapy Drugs Work [Internet]. American Cancer Society. 2019:1-9.

40. Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017;5.
41. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: A review of adverse toxicities and novel delivery strategies. *Expert Opinion on Drug Safety*. 2007;6:609–6021.
42. Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy K, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. *Indian J Pharmacol*. 2010;42(1):40.
43. Gold JM, Raja A. Cisplatin. *StatPearls*. 2024.
44. McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: Pathophysiology, current and emerging treatments. *Frontiers Media S.A*. 2016;7:1–9.
45. Tsao LR, Young FD, Otani IM, Castells MC. Hypersensitivity Reactions to Platinum Agents and Taxanes. *Clinical Reviews in Allergy and Immunology*. Springer. 2022;62(3):432–448.
46. Zajaczkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. *International Journal of Molecular Sciences*. 2019;20(6):2–29.
47. Wikramanayake TC, Haberland NI, Akhundlu A, Laboy Nieves A, Miteva M. Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?. *Current Oncology*. 2023;30:3609–3626.
48. Conte E, Bresciani E, Rizzi L, Cappellari O, De Luca A, Torsello A, et al. Cisplatin-induced skeletal muscle dysfunction: Mechanisms and counteracting therapeutic strategies. *International Journal of Molecular Sciences*. 2020;21:1–19.
49. Dillard L, Lopez-Perez L, Martinez R, Fullerton A, Chadha S, McMahon C. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. *PubMed Central*. 2022.
50. Widjaja G, Gunawan VL. *Diagnosis dan Tata Laksana Tinitus*. 2023;5.
51. Purba E, Purba B, Syafii A, Khairad F, Damanik D, Siagian V, et al. *FullBook Metode Penelitian Ekonomi*. Yayasan Kita Menulis. 2021
52. Alimin A, Ardhani Pratama A, Vivaldi Kuhuwael R, Baso Sulaiman A, et al. *Perbandingan Karakteristik Pasien Karsinoma Nasofaring Yang Merokok*

Dan Tidak Merokok Di Rumah Sakit Pelamonia Makassar Tahun 2020-2022. *Jurnal Kesehatan Masyarakat*. 2024;8(1):729–38.

53. Akhmad CN, Pieter NAL. Profile of Nasopharyngeal Carcinoma in Dr. Wahidin Sudirohusodo Hospital Makassar 2011 – 2021. In 2023:185–189.
54. Hakim A, Wahyudin E, Pieter NAL. Effects of Combination of Cisplatin and Paclitaxel Chemotherapy on Tumor Mass in Nasopharyngeal Carcinoma Patients at Dr. Wahidin Sudirohusodo Hospital Makassar with the RECIST Method. *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy)*. 2023;9(2):189–96.
55. Utami N, Harianto, Winarto. Gambaran penderita karsinoma nasofaringdi poliklinik THT RSUD Arifin Achmad Provinsi Riau dari Tahun 2016 – 2020. *Jurnal Kedokteran Syiah Kuala*. 2022;22:261–7.
56. Prayogi J, Tenri Sanna A, Carolina J. Karakteristik Pasien Penderita Karsinoma Nasofaring Di Indonesia: Narrative Review. 2024;5(2):5495–5501.
57. Awwad S, Ali A, Alshaikh F, Alomtari M. Assessment of chemotherapy-induced nausea and vomiting in pediatrics: Adequacy of control and adherence to guidelines. *Pediatric Hematology Oncology Journal*. 2023;8(3):171–8.
58. Amalia R, Sri Purwati Ningsih E. Literature Review Pengaruh Ekstrak Jahe terhadap Mual Muntah Pasien Kanker Paska Kemoterapi. *Jurnal Citra Keperawatan*. 2021;9.
59. Safitri IW, Padoli P, Puspitadewi TR. Actions To Reduce Nausea And Vomiting In Cancer Patients Undergoing Chemotherapy. 2021;15.
60. Fathonah, Rosyidatun. Identifikasi Efek Samping Kemoterapi Pada Penderita Kanker Di Yayasan Kanker Sindonesia Mulyorejo. *Jurnal Universitas Muhammadiyah Surabaya*. 2018:1–19.
61. Wikramanayake TC, Haberland NI, Akhundlu A, Laboy Nieves A, Miteva M. Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?. *Current Oncology*. 2023;30:3609-3626.
62. Zulkarnain I, Surarso B, Purnami N. Penurunan Hemoglobin, Neutrofil, Dan Trombosit Pascakemoterapi Cisplatin-Paclitaxel Pada Penderita Tumor Ganas Kepala Dan Leher. *Jurnal THT-KL*. 2017;10(1):1–10.